Panklav 2X

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panklav 2X

Panklav 2X is a highly specialized, synthetic fixed-dose combination antibacterial medication classified as a potentiated β-Lactam antibiotic belonging to the Penicillin group. It is designated as an Access group antibiotic, and is a prescription-only medicine intended to overcome bacterial resistance.


Property Description
Active ingredients Amoxicillin, Clavulanic acid
Form Film-coated tablets, Powder for oral suspension
Pharmacological class Potentiated β-Lactam Antibiotic
General purpose Treats infections caused by susceptible bacteria
Origin Synthetic
Rx Status Prescription-only

What Type of Medicine is Panklav 2X?

Panklav 2X is a broad-spectrum antibiotic that acts as an effective antibacterial agent for systemic infections in both adults and children. The medicine is supplied for oral administration, most frequently as film-coated tablets but also available as a powder for oral suspension. Its pharmacological classification confirms it as a potentiated aminopenicillin. The product's specific 2X designation is a differentiating factor, indicating a high-strength formulation compared to base-level combinations, often intended for specific dosing regimens.

Composition and Form: Amoxicillin with Clavulanic Acid

Panklav 2X incorporates two distinct active ingredients: Amoxicillin and Clavulanic acid (typically supplied as potassium clavulanate). The combination achieves a crucial synergistic action: Amoxicillin provides the core bactericidal action, while Clavulanic acid functions as a highly effective β-Lactamase inhibitor. This inhibitory action protects the antibiotic from degradation by bacterial enzymes.

The addition of clavulanic acid restores the activity of amoxicillin against most β-lactamase-producing bacteria. This mechanism supports the combination's therapeutic value in neutralizing the bacterial resistance mechanism bypass.

General Purpose: Why is Panklav 2X a Combination Drug?

The general purpose of using this combination is to directly address β-lactamase-producing organisms, which are increasingly common in the clinical setting. The strategic formulation allows Panklav 2X to be reliably used to resolve systemic infections where high-level antimicrobial activity against common and resistant bacterial populations is required. This makes the medicine suitable for managing infections like acute bacterial sinusitis and acute otitis media, which are often associated with resistant strains.

What side effects are possible with Panklav 2X?

Possible Side Effects and Safety Information

Panklav 2X, a combination of amoxicillin and clavulanic acid, is an antibiotic that belongs to the penicillin class. While generally well-tolerated, it is associated with a risk profile that includes both common and serious adverse reactions.

Adverse Reactions

The most frequent side effects reported are gastrointestinal, affecting up to 1 in 10 patients. These common reactions include diarrhea, nausea, vomiting, and mucocutaneous candidiasis (thrush). Taking the medication with food may help reduce gastrointestinal upset.

Serious or clinically significant adverse reactions are rare but require immediate attention. These include severe hypersensitivity reactions such as anaphylaxis, angioedema, and serious skin conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Hepatic events, including hepatitis and cholestatic jaundice, have also been reported; this risk may be higher in elderly patients, males, and with treatment duration exceeding 14 days.

Other rare, severe effects include Clostridioides difficile-associated diarrhea (CDAD) and a type of allergic reaction primarily affecting the gut, known as Drug-Induced Enterocolitis Syndrome (DIES).

Classification Examples of Reactions
Common Diarrhea, Nausea, Vomiting, Candidiasis
Rare Hepatic dysfunction, Severe skin reactions, Colitis, Seizures

Safety Considerations

The use of Panklav 2X is contraindicated in individuals with a history of allergic reaction (hypersensitivity) to any penicillin or other beta-lactam antibiotics. It is also contraindicated in patients who have a prior history of liver problems (jaundice or hepatic dysfunction) specifically linked to taking amoxicillin/clavulanic acid.

Patients with known renal impairment typically require a dosage adjustment to prevent accumulation of the drug. Caution is also advised for those with known hepatic impairment (liver disease) or infectious mononucleosis, as a non-allergic rash may occur in the latter. Laboratory monitoring of renal, hepatic, and hematological function is recommended during prolonged therapy.

Overdose and Emergency Response

Overdose and when to seek help

The information below details the official overdose profile for Panklav 2X, based strictly on government regulatory documents.

Overdose Scope
Documented overdose presentations: Gastrointestinal symptoms (diarrhea, vomiting, stomach pain), Central Nervous System effects (agitation, drowsiness, hyperactivity, and convulsions), and urological changes (decreased frequency or amount of urination).
Physiological systems affected (as stated in label): Gastrointestinal, Central Nervous, and Renal/Urinary systems.
Dose-related or exposure-related factors (if applicable): High exposure levels carry a risk of Amoxicillin crystalluria (drug crystals in the urine), which can lead to kidney impairment.
Population-specific overdose notes (if applicable): Patients with pre-existing impaired renal function are at increased risk of neurological effects, including convulsions, due to reduced drug clearance.
Emergency-response statements (as written in official documents): Seek immediate medical attention or call a Poison Control Center. Management includes procedural steps like Hemodialysis (effective for drug removal) and fluid/electrolyte support.
When immediate medical help is required (label-derived phrasing only): If overdose symptoms are observed, or if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Classification Item
Severity classification (as defined in official documents): Severe cases are associated with neurological symptoms and potential renal impairment from crystalluria.
Overdose-context constraints (as defined in official documents): No specific antidote is documented in the official prescribing information.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may result in severe gastrointestinal upset and CNS effects, including documented events of convulsions/seizures.
  • The risk of crystalluria is a documented complication of overdose, potentially causing urological changes and renal impairment.
  • Immediate medical attention is required for overdose, and hemodialysis is a recognized procedural step for drug removal in severe cases.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by specific risks to the CNS and renal systems, particularly in the context of impaired kidney function. The official instructions mandate that immediate help be sought when documented overdose symptoms occur, due to the potential for serious complications that require procedural management like hemodialysis.

Therapeutic Uses of Panklav 2X

What Panklav 2X Treats: Main Uses and Benefits

Panklav 2X (Amoxicillin and Clavulanate Potassium) is commonly used to help manage significant symptoms associated with acute or episodic changes. The core therapeutic domain of this medication is relevant in contexts involving heightened systemic burden across domains such as the respiratory tract, sinuses, and urinary system. It is also relevant for easing symptoms linked to skin and skin structure conditions. It is applied across domains where additional symptomatic support is needed.

This medication is commonly used across conditions presenting with acute episodes and recurrent or episodic manifestations. It helps address symptom clusters that may become intense or disruptive and create noticeable physiological strain. When symptoms intensify, supportive relief is needed. The medication helps maintain a sense of stability when symptoms are more noticeable, contributing to improved comfort during periods of heightened symptoms. It is used in clinical settings that involve acute or unstable symptom patterns.


Quick Fact: Management of Symptoms that Interfere with Daily Functioning

Panklav 2X helps address symptoms that interfere with daily functioning. It is generally applied in scenarios where short-term symptomatic assistance is needed to manage symptom clusters that may become intense or disruptive.

Eligibility and Restrictions for Use

Panklav 2X is a prescription-only medicine with eligibility defined by official regulatory criteria, primarily related to allergy history, existing medical conditions, and age.

Contraindications and Absolute Non-Eligibility

Category Restriction
Hypersensitivity Contraindicated in patients with a history of serious allergic reactions (including anaphylaxis) to any penicillin antibiotic, Amoxicillin, Clavulanate, or other beta-lactam antibiotics.
Prior Liver Injury Contraindicated if a patient has a history of cholestatic jaundice or hepatic dysfunction specifically associated with previous use of Amoxicillin/Clavulanate.

Condition-Based and Age-Related Restrictions

  • Infectious Mononucleosis: Use should be avoided due to the high likelihood of developing a non-allergic skin rash.
  • Renal Impairment: Use requires caution, and dosage adjustment is officially required for patients with severe renal impairment (GFR < 30 mL/min). Certain high-strength forms are not recommended in this population.
  • Pediatric Patients: Use is established for pediatric patients 12 weeks (3 months). Infants < 12 weeks are eligible, but require specific dose modification due to physiological maturity.
  • Pregnancy and Lactation: The medicine is categorized as Pregnancy Category B (FDA). Use is conditional and should occur only if clearly needed. Caution is advised for nursing mothers as active ingredients are excreted in breast milk.

What should I know about interactions with other medicines?

The official interaction profile for Panklav 2X is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

The co-administration of the uricosuric agent Probenecid is not recommended because this interaction formally decreases the renal tubular secretion of the amoxicillin component, resulting in increased and prolonged blood concentrations of the medicine.

Pharmacodynamic interactions are documented with Oral Anticoagulants, where concurrent use may officially increase the prolongation of prothrombin time (INR), and with Allopurinol, which officially increases the incidence of rash. Additionally, Panklav 2X may lead to reduced efficacy of Combined Oral Contraceptives due to a potential alteration in estrogen reabsorption.

Regarding timing constraints, administration at the start of a meal is required to enhance the absorption of the clavulanate component, a rule based on a food interaction outcome. A specific restriction dictates that Anti-peristaltic medicines are formally contra-indicated during antibiotic-associated colitis.

Finally, an interaction with laboratory tests is documented, where the medication can cause false-positive results for urinary glucose (non-enzymatic methods) and the Coombs test. This official information establishes specific substance prohibitions, exposure modifications, and procedural requirements.

Mechanism of Action

Dual Targeting of Bacterial Defense and Structure

Panklav 2X operates via a synergistic dual mechanism against bacterial structures and their defense enzymes. The first component, Clavulanic acid, acts as a beta-lactamase inhibitor, binding covalently to and irreversibly inactivating the bacterial beta-lactamase enzymes. This action mitigates the enzymatic inactivation of the second component, Amoxicillin.

Inhibiting Bacterial Cell Wall Synthesis

Amoxicillin is an antibiotic that targets Penicillin-Binding Proteins (PBPs), which are transpeptidase enzymes essential for the peptidoglycan synthesis pathway. Amoxicillin binds covalently to and inactivates these PBPs, preventing the necessary cross-linking step for cell wall rigidity. This mechanistic cascade results in a structurally unsound cell wall, leading to the rapid ingress of water via osmosis, causing cell lysis and the ultimate bactericidal effect.

Dosage and Administration Information

Panklav 2X is administered either orally (as tablets, chewable tablets, or suspension) or intravenously (as a powder for solution for infusion), depending on the specific product formulation. The medicine must be taken at the start of a meal or with the first mouthful of food to optimize the absorption of the clavulanate component.

The standard adult regimen typically follows a twice-daily (q12h) schedule, such as the 875 mg/125 mg strength, or a three-times-daily (q8h) schedule, depending on the prescribed dose. Treatment should not exceed 14 days without clinical reassessment.

Administration Rules and Adjustments

Parameter Official Instruction
Form Handling Extended-release (XR) tablets must be swallowed whole and must not be crushed, broken, or chewed. Oral suspensions require reconstitution with water and shaking prior to use.
Dose Timing Doses should be spaced as evenly as possible. If a dose is missed, it should be taken as soon as possible, ensuring the interval before the next dose is at least four hours.
Renal Impairment Dosage requires mandatory reduction if Creatinine Clearance (CrCl) is leq 30 mL/min. The 875 mg strength is generally not recommended in this population.

These instructions establish a meal-dependent protocol for use that governs the administration frequency and preparation of the various forms, ensuring the completion of the short-term course as prescribed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Panklav 2X

The following summary describes the type of clinical research conducted for Panklav 2X (Amoxicillin/Clavulanate), outlining what researchers studied, what findings were described, and what remains uncertain. This is a descriptive overview and should not be interpreted as medical advice or a statement of individual expected outcomes. Study results reflect the specific conditions under which they were conducted.


Evidence for use in Respiratory and Sinus Infections

Panklav 2X was studied for conditions involving the respiratory tract, focusing on acute bacterial sinusitis and lower respiratory tract infections such as community-acquired pneumonia. The evidence base primarily consists of Randomized Controlled Trials (RCTs) and Systematic Reviews. For acute bacterial sinusitis, studies monitored patient-reported outcomes describing perceived discomfort and clinical endpoints like the resolution of symptoms. Data show patterns related to clinical improvement and bacteriological eradication rates that were observed in some studies. Research suggests that for milder episodes where resistance is not confirmed, the added value of the combination over amoxicillin alone may be uncertain.

Evidence for use in Middle Ear and Urinary Tract Infections

Panklav 2X was evaluated in clinical trials for both acute bacterial otitis media and acute urinary tract infections (UTIs). For acute otitis media, studies were observed in children (including infants ge 3 months) and adults, and examined outcomes related to systemic or functional imbalance and bacteriological eradication. For urinary tract infections, research examined the medicine's use, mostly in adults with acute infections. Trials monitored outcomes such as bacteriological eradication and the presence of relapse or re-infection during the follow-up period. The overall evidence level for UTIs is described as Moderate.

Current Research Gaps and Uncertainties

While a substantial research base exists, certain aspects of the medicine’s use remain not fully established. Long-term effects are not fully established; the follow-up durations were limited in many primary clinical trials, meaning the research provides limited information for long-term outcomes, such as the maintenance of daily functioning or activity level or rates of recurrence over extended periods. For many indications, data for certain groups remain insufficient to determine if their response patterns differ from younger patients.

Key Studies & References

  1. Label: AMOXICILLIN AND CLAVULANATE POTASSIUM tablet, film coated (Official FDA Label)
  2. Antibiotic treatment of acute and recurrent otitis media in children: an Italian intersociety Consensus (Referencing dosing/comparison for Otitis Media)

Frequently Asked Questions (FAQ)

Common questions about Panklav 2X (FAQ)

Q: What kind of infections does Panklav 2X usually treat?

A: According to official product information, Panklav 2X (amoxicillin/clavulanate) is indicated for treating infections caused by certain susceptible bacteria. This includes infections of the lower respiratory tract, acute bacterial otitis media (middle ear infection), sinusitis, infections of the skin and soft tissues, and urinary tract infections. It is a prescription-only medicine.


Q: How quickly does Panklav 2X start working?

A: Regulatory drug information does not provide a specific time frame for when a person should start feeling better. The active components typically reach their highest concentration in the bloodstream within approximately 1 to 2.5 hours after an oral dose. Information regarding the time course of clinical response is not typically detailed in official documents.


Q: How long does the effect of Panklav 2X last in the body?

A: The elimination half-life of the amoxicillin component, which shows how quickly it is processed, is about 1 to 1.5 hours in adults with normal kidney function. This rate determines why the medication is prescribed on a twice-daily or thrice-daily schedule. The prescribed schedule is designed to maintain consistent levels of the active ingredients.


Q: Can Panklav 2X affect liver function?

A: Yes, official regulatory documents list hepatic dysfunction, which includes conditions like hepatitis and cholestatic jaundice, as a reported adverse reaction, although it is uncommon. Regulatory documents indicate caution is advised for patients with existing liver problems. The use of this drug in that population may be associated with specific clinical considerations.


Q: Is Panklav 2X approved for use during pregnancy?

A: The medicine is generally categorized as Pregnancy Category B by the FDA. Official information indicates use is reserved for situations when the medicine is clearly needed. Regulatory documents state there are no adequate and well-controlled studies in pregnant women.


Q: Is Panklav 2X classified as safe for breastfeeding?

A: Official information advises caution for nursing mothers. Low levels of the active ingredients are known to pass into human breast milk. Because components are excreted in breast milk, there is a possibility of effects in the infant, such as sensitization, diarrhea, or candidiasis (thrush).


Q: Does Panklav 2X interact with birth control pills?

A: Yes, regulatory documentation states that, like other broad-spectrum antibiotics, amoxicillin/clavulanate may officially reduce the efficacy of combined oral contraceptives. Official labeling notes this possibility as an important interaction.


Q: Does Panklav 2X interact with alcohol?

A: Official regulatory prescribing information for amoxicillin/clavulanate does not list a specific drug-drug interaction warning between this medicine and alcohol consumption.


Q: Are there any known long-term effects of using Panklav 2X?

A: Regulatory documents recommend that the duration of treatment should not exceed 14 days without clinical re-evaluation. Because most clinical trials have limited follow-up periods, information regarding any long-term effects extending significantly beyond the required short course of treatment is not fully established in the primary research base.


Q: Why do official sources recommend taking Panklav 2X at a specific time relative to meals (informational)?

A: Official guidelines indicate that administration occurs at the start of a meal or with the first mouthful of food. This is done to minimize the chance of gastrointestinal upset and to ensure optimal absorption of the clavulanate component into the body.


Q: Why is it called Panklav 2X?

A: The name 'Panklav 2X' is a specific brand name. The '2X' designation is often used in this class of antibiotics to indicate a high-strength, twice-daily dosing formulation (e.g., 875 mg/125 mg). This dosing was developed to simplify the regimen compared to older combinations requiring three doses per day.


Q: Does Panklav 2X have a generic version?

A: Yes. The combination of amoxicillin and clavulanate potassium, which are the active ingredients, is widely available in generic formulations. Generic formulations containing the same active ingredients are available.


Q: Is Panklav 2X commonly prescribed for children?

A: Regulatory documents confirm that the medicine is indicated and has specific dosing regimens for pediatric patients. It is used to treat common childhood conditions such as acute bacterial otitis media (middle ear infection) and certain lower respiratory tract infections.


Q: What is the difference between Panklav 2X and regular Panklav?

A: The key difference usually lies in the drug concentration. The '2X' designation refers to a high-strength formulation, often featuring a specific ratio of amoxicillin-to-clavulanate (e.g., 7:1) that permits effective twice-daily (BID) dosing, whereas 'regular' or older versions might require dosing three times per day (TID).


Q: Does Panklav 2X treat viral infections?

A: No. Official regulatory labeling explicitly specifies that this medicine is an antibacterial drug. It is indicated only for the treatment of infections caused by susceptible bacteria, and is not authorized for use against viral infections.


Q: Are there any age limits for using Panklav 2X?

A: Yes, regulatory documents establish use in pediatric patients beginning at 12 weeks of age (3 months) and older. Specific dose adjustments are officially required for infants younger than 12 weeks due to physiological maturity.


Q: Can Panklav 2X cause a skin rash?

A: Yes. Official documents list skin rash, including maculopapular rash and urticaria (hives), as known side effects. A rash can range from a common, non-allergic reaction to a sign of a more serious hypersensitivity event.


Q: What happens if I miss a dose of Panklav 2X (informational, non-directive)?

A: Regulatory documents describe the necessary adjustments when a dose is missed, such as ensuring a minimum time interval before the next scheduled dose (e.g., four hours). This is important because the timing is necessary to maintain the constant level of antibiotic needed to stop the growth of bacteria effectively.


Q: Can Panklav 2X be used for dental infections?

A: While regulatory documents do not list 'dental infections' specifically by name, the medicine is indicated for treating 'skin and skin structure infections.' It is commonly used in clinical settings for odontogenic (dental) and orofacial infections due to its broad bacterial target profile.


Q: Does Panklav 2X cause photosensitivity (increased sun sensitivity)?

A: Photosensitivity is not listed among the commonly reported or clinically significant adverse reactions in the official regulatory prescribing documents for this medicine.


Q: Is there a liquid or suspension form of Panklav 2X?

A: Yes. In addition to tablets, official documents confirm the medicine is supplied as a powder for oral suspension. This form is prepared by mixing the powder with water (reconstitution) and is used when a patient cannot take tablets.


Q: What is the chemical name for Panklav 2X?

A: The combined chemical name for the active components is Amoxicillin and Clavulanate Potassium.


Q: What is the difference between Panklav 2X and Augmentin?

A: Augmentin is the widely recognized, original brand name for the combination of amoxicillin and clavulanate potassium. Panklav 2X is a brand name used by a different company for the same active ingredients and high-strength formulation. Regulatory bodies identify both products as containing the same active ingredients.


Q: Is Panklav 2X available over the counter in any country?

A: In most major regulatory jurisdictions, including the United States and countries in the European Union, Amoxicillin/Clavulanate is legally classified as a prescription-only medicine (POM) or 'Rx only.' It is not available for purchase without a prescription.


Q: Can Panklav 2X cause yeast infections?

A: Yes. Official regulatory information lists mucocutaneous candidiasis (often called thrush or a yeast infection) as a common adverse reaction associated with this antibiotic. This occurs because the antibiotic can disrupt the natural balance of microorganisms in the body.


Q: Does the strength of Panklav 2X (e.g., 875/125 mg) matter for different infections?

A: Yes. Regulatory documents specify that different strengths and dosing regimens are indicated for varying types and severities of infection. For instance, high strengths like the 875 mg amoxicillin component are often specified for respiratory tract infections and more severe cases.


Q: Can Panklav 2X affect the results of blood tests?

A: Yes. Regulatory warnings state that the medicine can officially cause false-positive results in certain laboratory tests. This includes specific tests for urinary glucose (non-enzymatic methods) and the Coombs test.


Q: Why do some people experience a metallic taste while using Panklav 2X?

A: Alterations in taste, technically called dysgeusia, are listed as a known, though rare, adverse reaction in regulatory documents. This type of taste disturbance is sometimes described as a metallic or unusual flavor.


Q: Is it normal to feel tired or dizzy while taking Panklav 2X?

A: Dizziness and fatigue (tiredness) are listed as known adverse reactions in the central nervous system effects section of official regulatory documents. While not categorized as common reactions, they are documented possibilities.


Q: Are there any foods or drinks I should avoid while taking Panklav 2X?

A: Regulatory guidance focuses only on the requirement to take the medication with a meal to enhance absorption. The official product information does not list any general prohibitions on consuming specific foods or non-alcoholic drinks.

How should Panklav 2X be stored and disposed of?

How to Store and Dispose of Panklav 2X?

Panklav 2X (Amoxicillin and Clavulanate Potassium) requires adherence to specific conditions to maintain product stability, as documented in official regulatory labeling.


Storage Requirements

Constraint Official Requirement
Temperature Store below 25^circC (77°F).
Protection Must be protected from light and moisture.
Packaging Store in the original container to protect from light.
Stability (Opened) Tablets must be used within 30 days of opening the protective pouch.

Child Safety and Disposal

All forms of this medicine must be kept out of the sight and reach of children.

Disposal instructions mandate that any unused or expired product must be discarded according to local regulations for pharmaceutical waste. Do not dispose of the medicine via household waste or wastewater unless specifically instructed to do so by local waste authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Panklav 2X found in:

A-Z Index: